{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:09Z","timestamp":1794047529379,"version":"4.8.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-90135-8","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:03:00Z","timestamp":1739955780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A real-world pharmacovigilance analysis of hepatitis B vaccine using the U.S. Vaccine Adverse Event Reporting System (VAERS) database"],"prefix":"10.1038","volume":"15","author":[{"given":"Huting","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongning","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"90135_CR1","unstructured":"World Health Organization (WHO). Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021: Actions for Impart. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/342813\/9789240030992-eng.pdf."},{"key":"90135_CR2","doi-asserted-by":"crossref","unstructured":"World Health Organization (WHO). Hepatitis B vaccines: WHO position paper, July 2017 \u2013 Recommendations. Vaccine 37, 223\u2013225 (2019).","DOI":"10.1016\/j.vaccine.2017.07.046"},{"key":"90135_CR3","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","volume":"33","author":"TT Shimabukuro","year":"2015","unstructured":"Shimabukuro, T. T., Nguyen, M., Martin, D. & DeStefano, F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 33, 4398\u20134405 (2015).","journal-title":"Vaccine."},{"key":"90135_CR4","unstructured":"Council for International Organizations of Medical Sciences (CIOMS). Definition and Application of Terms for Vaccine Pharmacovigilance: Report of CIOMS\/WHO Working Group on Vaccine Pharmacovigilance. (WHO Press, World Health Organization, 2012)."},{"key":"90135_CR5","first-page":"1","volume":"54","author":"EE Mast","year":"2005","unstructured":"Mast, E. E. et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP): Part 1: Immunization of infants, children, and adolescents. Morbidity Mortality Wkly. Rep. 54, 1\u201331 (2005).","journal-title":"Morbidity Mortality Wkly. Rep."},{"key":"90135_CR6","first-page":"1","volume":"55","author":"EE Mast","year":"2006","unstructured":"Mast, E. E. et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of adults. Morbidity Mortality Wkly. Rep. 55, 1\u201333 (2006).","journal-title":"Morbidity Mortality Wkly. Rep."},{"key":"90135_CR7","unstructured":"FDA.gov. Package Insert - Recombivax HB. https:\/\/www.fda.gov\/media\/74274\/download (1989)."},{"key":"90135_CR8","unstructured":"GSK-China. Instructions for Recombinant Hepatitis B Vaccine (Saccharomyces cerevisiae). https:\/\/www.gsk-china.com\/media\/6246\/engerix-leaflet_ppc-0012599.pdf (2020)."},{"key":"90135_CR9","first-page":"69","volume":"23","author":"F Zeng","year":"2023","unstructured":"Zeng, F. et al. Efficacy and safety of hepatitis B vaccine: An umbrella review of meta-analyses. Exp. Rev. Vac. 23, 69\u201381 (2023).","journal-title":"Exp. Rev. Vac."},{"key":"90135_CR10","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/14760584.2017.1338568","volume":"16","author":"C Van Den Ende","year":"2017","unstructured":"Van Den Ende, C., Marano, C., Van Ahee, A., Bunge, E. M. & De Moerlooze, L. The immunogenicity and safety of GSK\u2019s recombinant hepatitis B vaccine in adults: A systematic review of 30 years of experience. Exp. Rev. Vac. 16, 811\u2013832 (2017).","journal-title":"Exp. Rev. Vac."},{"key":"90135_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11595670-000000000-00000","volume":"35","author":"MC Makris","year":"2012","unstructured":"Makris, M. C. et al. Safety of hepatitis B, pneumococcal polysaccharide and meningococcal polysaccharide vaccines in pregnancy. Drug Saf. 35, 1\u201314 (2012).","journal-title":"Drug Saf."},{"key":"90135_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/00006454-200404000-00002","volume":"23","author":"F Varricchio","year":"2004","unstructured":"Varricchio, F. et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr. Infect. Dis. J. 23, 287\u2013294 (2004).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"90135_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3928\/0090-4481-20040901-11","volume":"33","author":"JK Iskander","year":"2004","unstructured":"Iskander, J. K., Miller, E. R. & Chen, R. T. The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety. Pediatr. Ann. 33, 599\u2013606 (2004).","journal-title":"Pediatr. Ann."},{"key":"90135_CR14","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1016\/S0264-410X(99)00132-2","volume":"17","author":"JA Singleton","year":"1999","unstructured":"Singleton, J. A., Lloyd, J. C., Mootrey, G. T., Salive, M. E. & Chen, R. T. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. VAERS Working Group. Vaccine. 17, 2908\u20132917 (1999).","journal-title":"Vaccine."},{"key":"90135_CR15","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli, M. et al. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and elaboration. Drug Saf. 47, 585\u2013599 (2024).","journal-title":"Drug Saf."},{"key":"90135_CR16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/14740338.2024.2368817","volume":"23","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli, M., Raschi, E., Poluzzi, E. & Hauben, M. The evolving role of disproportionality analysis in pharmacovigilance. Expert Opin. Drug Saf. 23, 981\u2013994 (2024).","journal-title":"Expert Opin. Drug Saf."},{"key":"90135_CR17","doi-asserted-by":"crossref","unstructured":"The Vaccine Adverse Event Reporting System (VAERS). Vaccine 12, 542\u201350 (1994).","DOI":"10.1016\/0264-410X(94)90315-8"},{"key":"90135_CR18","doi-asserted-by":"crossref","unstructured":"Chen, R.T. et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 12, 542\u2013550 (1994).","DOI":"10.1016\/0264-410X(94)90315-8"},{"key":"90135_CR19","unstructured":"Centers for Disease Control and Prevention (CDC). About The Vaccine Adverse Event Reporting System (VAERS). The Vaccine Adverse Event Reporting System (VAERS) Request Form (cdc.gov)."},{"key":"90135_CR20","unstructured":"Centers for Disease Control and Prevention (CDC). Manual for the Surveillance of Vaccine-Preventable Diseases. https:\/\/www.cdc.gov\/vaccines\/pubs\/surv-manual\/index.html (2024)."},{"key":"90135_CR21","unstructured":"MedDRA. Medical Dictionary for Regulatory Activities: MedDRA Hierarchy."},{"key":"90135_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"E van Puijenbroek","year":"2002","unstructured":"van Puijenbroek, E. et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol. Drug Saf. 11, 3\u201310 (2002).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"90135_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans, S. J. W., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10, 483\u2013486 (2001).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"90135_CR24","doi-asserted-by":"crossref","unstructured":"Bate, A. et al. Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs. Eur. J. Clin. Pharmacol. 58, 483\u2013490 (2002).","DOI":"10.1007\/s00228-002-0484-z"},{"key":"90135_CR25","unstructured":"European Medicines Agency. Signal Management\u2014Designated Medical Events. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/pharmacovigilance\/signal-management#designated-medical-events-section (2023)."},{"key":"90135_CR26","first-page":"188","volume":"44","author":"R Fu","year":"2023","unstructured":"Fu, R. & Wang, T. Interpretiation of guidelines for the diagnosis and management of aplastic anemia in China (2022). Zhonghua Xue Ye Xue Za Zhi. 44, 188\u2013192 (2023).","journal-title":"Zhonghua Xue Ye Xue Za Zhi."},{"key":"90135_CR27","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/S0140-6736(05)66515-4","volume":"365","author":"RA Brodsky","year":"2005","unstructured":"Brodsky, R. A. & Jones, R. J. Aplastic anaemia. Lancet 365, 1647\u20131656 (2005).","journal-title":"Lancet"},{"key":"90135_CR28","doi-asserted-by":"publisher","first-page":"e01826","DOI":"10.1016\/j.idcr.2023.e01826","volume":"33","author":"PVS Smruthi","year":"2023","unstructured":"Smruthi, P. V. S. et al. An unusual case of acquired aplastic anemia following SARS-CoV-2 vaccination: A case report. IDCases 33, e01826\u2013e01826 (2023).","journal-title":"IDCases"},{"key":"90135_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102782","volume":"126","author":"S Tabata","year":"2022","unstructured":"Tabata, S. et al. Severe aplastic anemia after COVID-19 mRNA vaccination: Causality or coincidence?. J. Autoimmun. 126, 102782 (2022).","journal-title":"J. Autoimmun."},{"key":"90135_CR30","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/jha2.443","volume":"3","author":"X Wang","year":"2022","unstructured":"Wang, X., Laczko, D., Caponetti, G. C., Rabatin, S. & Babushok, D. V. Severe aplastic anaemia after serial vaccinations for SARS-CoV-2, pneumococcus and seasonal influenza. EJHaem. 3, 983\u2013988 (2022).","journal-title":"EJHaem."},{"key":"90135_CR31","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1182\/bloodadvances.2019000853","volume":"4","author":"C Ritz","year":"2020","unstructured":"Ritz, C. et al. Postvaccination graft dysfunction\/aplastic anemia relapse with massive clonal expansion of autologous CD8+ lymphocytes. Blood Adv. 4, 1378\u20131382 (2020).","journal-title":"Blood Adv."},{"key":"90135_CR32","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/S0140-6736(05)66515-4","volume":"365","author":"RA Brodsky","year":"2005","unstructured":"Brodsky, R. A. & Jones, R. J. Aplastic anaemia. Lancet. 365, 1647\u20131656 (2005).","journal-title":"Lancet."},{"key":"90135_CR33","doi-asserted-by":"crossref","unstructured":"Ashok Shenoy, K., Adhikari, P. Chakrapani, M., Shenoy, D. & Pillai, A. Pancytopenia after recombinant hepatitis B vaccine \u2013 An Indian case report. Br. J. Haematol. 114, 954\u2013962 (2001).","DOI":"10.1046\/j.1365-2141.2001.03006-2.x"},{"key":"90135_CR34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1046\/j.1365-2141.2000.02171.x","volume":"110","author":"J-F Viallard","year":"2000","unstructured":"Viallard, J.-F. et al. Severe pancytopenia triggered by recombinant hepatitis B vaccine. Br. J. Haematol. 110, 230\u2013233 (2000).","journal-title":"Br. J. Haematol."},{"key":"90135_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjh.13853","volume":"172","author":"SB Killick","year":"2016","unstructured":"Killick, S. B. et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br. J. Haematol. 172, 187\u2013207 (2016).","journal-title":"Br. J. Haematol."},{"key":"90135_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/0019-5154.48976","volume":"54","author":"C Okoduwa","year":"2009","unstructured":"Okoduwa, C. et al. Erythroderma: Review of a potentially life-threatening dermatosis. Indian J. Dermatol. 54, 1\u20136 (2009).","journal-title":"Indian J. Dermatol."},{"key":"90135_CR37","doi-asserted-by":"crossref","unstructured":"Tso, S. et al. Erythroderma (exfoliative dermatitis). Part 1: Underlying causes, clinical presentation and pathogenesis. Clin. Exp. Dermatol. 46, 1001\u20131010 (2021).","DOI":"10.1111\/ced.14625"},{"key":"90135_CR38","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1017\/S0950268800030740","volume":"103","author":"CA Morris","year":"1989","unstructured":"Morris, C. A., Oliver, P. R., Reynolds, F. & Selkon, J. B. Intradermal hepatitis B immunization with yeast-derived vaccine: Serological response by sex and age. Epidemiol. Infect. 103, 387\u2013394 (1989).","journal-title":"Epidemiol. Infect."},{"key":"90135_CR39","first-page":"13","volume":"14","author":"D J\u00fanior","year":"2020","unstructured":"J\u00fanior, D. Environmental and individual factors associated with protection and predisposition to autoimmune diseases. Int. J. Health Sci. (Qassim). 14, 13\u201323 (2020).","journal-title":"Int. J. Health Sci. (Qassim)."},{"issue":"4","key":"90135_CR40","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","volume":"33","author":"R Coffman","year":"2010","unstructured":"Coffman, R., Sher, A. & Seder, R. Vaccine adjuvants: Putting innate immunity to work. Immunity 33(4), 492\u2013503 (2010).","journal-title":"Immunity"},{"key":"90135_CR41","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejim.2009.12.001","volume":"21","author":"G Lippi","year":"2010","unstructured":"Lippi, G., Targher, G. & Franchini, M. Vaccination, squalene and anti-squalene antibodies: Facts or fiction?. Eur. J. Internal Med. 21, 70\u201373 (2010).","journal-title":"Eur. J. Internal Med."},{"key":"90135_CR42","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12098-019-03119-8","volume":"87","author":"M Jamwal","year":"2020","unstructured":"Jamwal, M., Sharma, P. & Das, R. Laboratory approach to hemolytic anemia. Indian J. Pediatr. 87, 66\u201374 (2020).","journal-title":"Indian J. Pediatr."},{"key":"90135_CR43","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1182\/blood.2019003810","volume":"137","author":"MR Thomas","year":"2021","unstructured":"Thomas, M. R. & Scully, M. How I treat microangiopathic hemolytic anemia in patients with cancer. Blood 137, 1310\u20131317 (2021).","journal-title":"Blood"},{"key":"90135_CR44","doi-asserted-by":"crossref","unstructured":"Scully, M. et al. A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies. Br. J. Haematol. 203 (2023).","DOI":"10.1111\/bjh.19026"},{"key":"90135_CR45","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0140-6736(94)90777-3","volume":"344","author":"P Poullin","year":"1994","unstructured":"Poullin, P. & Gabriel, B. Thrombocytopenic purpura after recombinant hepatitis B vaccine. Lancet. 344, 1293 (1994).","journal-title":"Lancet."},{"key":"90135_CR46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/01.inf.0000109846.59440.a1","volume":"23","author":"H Nuevo","year":"2004","unstructured":"Nuevo, H., Nascimento-Carvalho, C. M. C., Athayde-Oliveira, C. P., Lyra, I. & Moreira, L. M. O. Thrombocytopenic purpura after hepatitis B vaccine: Case report and review of the literature. Pediatric Infect. Dis. J. 23, 183\u2013184 (2004).","journal-title":"Pediatric Infect. Dis. J."},{"key":"90135_CR47","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/adc.78.3.273","volume":"78","author":"F Ronchi","year":"1998","unstructured":"Ronchi, F. et al. Thrombocytopenic purpura as adverse reaction to recombinant hepatitis B vaccine. Arch. Dis. Childh. 78, 273\u2013274 (1998).","journal-title":"Arch. Dis. Childh."},{"key":"90135_CR48","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1093\/ndt\/13.9.2420","volume":"13","author":"P Finielz","year":"1998","unstructured":"Finielz, P., Lam-Kam-Sang, L. & Guiserix, J. Systemic lupus erythematosus and thrombocytopenic purpura in two members of the same family following hepatitis B vaccine. Nephrol. Dial. Transplant. 13, 2420\u20132421 (1998).","journal-title":"Nephrol. Dial. Transplant."},{"key":"90135_CR49","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1016\/j.vaccine.2006.10.054","volume":"25","author":"J Rajantie","year":"2007","unstructured":"Rajantie, J., Zeller, B., Treutiger, I. & Rosth\u00f6j, S. Vaccination associated thrombocytopenic purpura in children. Vaccine. 25, 1838\u20131840 (2007).","journal-title":"Vaccine."},{"key":"90135_CR50","doi-asserted-by":"publisher","first-page":"6495","DOI":"10.1016\/j.vaccine.2008.09.062","volume":"26","author":"A Polat","year":"2008","unstructured":"Polat, A., Akca, H. & Dagdeviren, E. Severe thrombocytopenia after hepatitis B vaccine in an infant from Turkey. Vaccine. 26, 6495\u20136496 (2008).","journal-title":"Vaccine."},{"key":"90135_CR51","first-page":"749","volume":"22","author":"MR Geier","year":"2004","unstructured":"Geier, M. R. & Geier, D. A. A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: Analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review. PubMed. 22, 749\u2013755 (2004).","journal-title":"PubMed."},{"key":"90135_CR52","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/08916930500144484","volume":"38","author":"DA Geier","year":"2005","unstructured":"Geier, D. A. & Geier, M. R. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity. 38, 295\u2013301 (2005).","journal-title":"Autoimmunity."},{"key":"90135_CR53","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1517\/14740338.2.2.113","volume":"2","author":"MR Geier","year":"2003","unstructured":"Geier, M. R., Geier, D. A. & Zahalsky, A. C. A review of hepatitis B vaccination. Exp. Opinion Drug Saf. 2, 113\u2013122 (2003).","journal-title":"Exp. Opinion Drug Saf."},{"key":"90135_CR54","unstructured":"CDC. Notice to Readers: Thimerosal in Vaccines: A Joint Statement of the American Academy of Pediatrics and the Public Health Service. https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm4826a3.htm (1999)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90135-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90135-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90135-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:37:01Z","timestamp":1739997421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90135-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["90135"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-90135-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"7 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Anonymized data were collected from a publicly available database and do not require ethics committee approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"6022"}}